Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2016 3
2017 2
2019 2
2020 7
2021 6
2022 2
2023 8
2024 8
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J; CheckMate 067 Investigators. Wolchok JD, et al. N Engl J Med. 2025 Jan 2;392(1):11-22. doi: 10.1056/NEJMoa2407417. Epub 2024 Sep 15. N Engl J Med. 2025. PMID: 39282897 Free PMC article. Clinical Trial.
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.
Chiffelle J, Barras D, Pétremand R, Orcurto A, Bobisse S, Arnaud M, Auger A, Rodrigo BN, Ghisoni E, Sauvage C, Saugy D, Michel A, Murgues B, Fahr N, Imbimbo M, Ochoa de Olza M, Latifyan S, Crespo I, Benedetti F, Genolet R, Queiroz L, Schmidt J, Homicsko K, Zimmermann S, Michielin O, Bassani-Sternberg M, Kandalaft LE, Dafni U, Corria-Osorio J, Trueb L, Dangaj Laniti D, Harari A, Coukos G. Chiffelle J, et al. Among authors: latifyan s. Immunity. 2024 Oct 8;57(10):2466-2482.e12. doi: 10.1016/j.immuni.2024.08.014. Epub 2024 Sep 13. Immunity. 2024. PMID: 39276771 Free article.
[2021 Oncology update].
Meyer ML, Chrysou K, Stamatiou A, Gilabert M, Herrera Gomez RG, Latifyan S, Masmoudi S, Mederos N, Perrinjaquet C, Berthold D, Bouchaab H, Cristina V, Digklia A, Michielin O, Orcurto A, Sarivalasis A, Stravodimou A, Wagner AD, Zaman K, Peters S, Jankovic J. Meyer ML, et al. Among authors: latifyan s. Rev Med Suisse. 2022 Feb 2;18(767):182-186. doi: 10.53738/REVMED.2022.18.767.182. Rev Med Suisse. 2022. PMID: 35107893 French.
[Oncology: what's new in 2022].
Nguyen-Ngoc T, Abdelhamid K, Degrauwe N, Galland S, Serena A, Christofis M, Mederos N, Bouchaab H, Diciolla A, Dris N, Orcurto A, Perrinjaquet C, Schnetz M, Latifyan S, Wetterwald L, Herrera Gómez RG, Cristina V, Sarivalasis A, Michielin O, Berthold D, Digklia A, Wagner AD, Zaman K, Peters S, Stravodimou A. Nguyen-Ngoc T, et al. Among authors: latifyan s. Rev Med Suisse. 2023 Jan 18;19(N° 809-10):52-57. doi: 10.53738/REVMED.2023.19.809-10.52. Rev Med Suisse. 2023. PMID: 36660838 French.
[Oncology: what's new in 2023].
Jankovic J, Abdelhamid K, Berthold D, Desbaillets N, Bouchaab H, Dei Tos G, Demicheli R, Diciolla A, Digklia A, Ferraro DA, Florez L, Galli-Vareia I, Hottinger A, Latifyan S, Liapi A, Mederos N, Giacomuzzi Moore B, Sakr R, Stamatiou A, Wagner AD, Peters S, Sarivalasis A, Vanniere F, Zaman K, Stravodimou A. Jankovic J, et al. Among authors: latifyan s. Rev Med Suisse. 2024 Jan 17;20(856-7):80-87. doi: 10.53738/REVMED.2024.20.856-7.80. Rev Med Suisse. 2024. PMID: 38231107 French.
Physical approaches to treat glioblastoma.
Latifyan S, de Micheli R, Hottinger AF. Latifyan S, et al. Curr Opin Oncol. 2020 Nov;32(6):640-649. doi: 10.1097/CCO.0000000000000689. Curr Opin Oncol. 2020. PMID: 32925205 Review.
[Advances in Oncology 2019].
Vernadou A, Ferahta N, Mederos N, Ferraro D, Dischl-Antonioni I, Diciolla A, Liapi A, Mosimann V, Latifyan S, Aedo-Lopez V, Berthold D, Digklia A, Michielin O, Montemurro M, Wagner AD, Zaman K, Peters S, Stravodimou A, Sarivalasis A. Vernadou A, et al. Among authors: latifyan s. Rev Med Suisse. 2020 Jan 15;16(676-7):72-77. Rev Med Suisse. 2020. PMID: 31961089 Review. French.
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.
Daoudlarian D, Segot A, Latifyan S, Bartolini R, Joo V, Mederos N, Bouchaab H, Demicheli R, Abdelhamid K, Ferahta N, Doms J, Stalder G, Noto A, Mencarelli L, Mosimann V, Berthold D, Stravodimou A, Sartori C, Shabafrouz K, Thompson JA, Wang Y, Peters S, Pantaleo G, Obeid M. Daoudlarian D, et al. Among authors: latifyan s. Ann Oncol. 2025 Apr;36(4):444-459. doi: 10.1016/j.annonc.2024.12.004. Epub 2024 Dec 17. Ann Oncol. 2025. PMID: 39701282 Free article.
[Oncology, what's new in 2018].
Latifyan S, Kakourou A, Ozdemir B, Zaman K, Vernadou A, Berthold D, Abdelhamid K, Bouchaab H, Peters S, Montemurro M, Aedo V, Michielin O, Zimmermann S, Stravodimou A. Latifyan S, et al. Rev Med Suisse. 2019 Jan 9;15(N° 632-633):78-81. Rev Med Suisse. 2019. PMID: 30629376 French.
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
Leone G, Orlando F, Dutey-Magni P, Vainauskas O, Grist E, Ciani Y, Lall S, Thakali S, Wingate A, Wetterskog D, Sachdeva A, Sydes MR, McPhail N, Sreenivasan T, O'Sullivan JM, Clarke NW, Parmar MKB, Brown LC, James ND, Demichelis F, Attard G; STAMPEDE collaborators. Leone G, et al. JAMA Oncol. 2025 Feb 27;11(4):426-9. doi: 10.1001/jamaoncol.2024.7051. Online ahead of print. JAMA Oncol. 2025. PMID: 40014335
43 results